Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleksei A Stepanenko

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Gene|September 2, 2018
A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapyAleksei A Stepanenko, Vladimir P Chekhonin
Biomedicines|December 1, 2019
On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent ResistanceAleksei A Stepanenko, Vladimir P Chekhonin
Virus Research|August 21, 2018
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIXAleksei A Stepanenko, Vladimir P Chekhonin
Cancers|December 20, 2018
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?Aleksei A Stepanenko, Vladimir P Chekhonin
Mutation Research. Reviews in Mutation Research|September 21, 2017
Transient and stable vector transfection: Pitfalls, off-target effects, artifactsAleksei A Stepanenko, Henry H Heng
Scientific Reports|August 10, 2021
A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugationAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Molecular Therapy Oncolytics|March 14, 2022
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Victor A Naumenko, Aleksei A Stepanenko, Anastasiia V Lipatova, et al.
Frontiers in Immunology|February 23, 2024
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapyAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Molecular Therapy. Oncology|February 20, 2026
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/<i>SPAM1</i>-armed oncolytic adenovirus Ad5Δ24RGDAleksei A Stepanenko, Anastasiia O Sosnovtseva, Anastasiia A Vasiukova, et al.
Frontiers in Immunology|March 14, 2024
Systemic and local immunosuppression in glioblastoma and its prognostic significanceAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Gene|September 2, 2018
A compendium of adenovirus genetic modifications for enhanced replication, oncolysis, and tumor immunosurveillance in cancer therapyAleksei A Stepanenko, Vladimir P Chekhonin
Biomedicines|December 1, 2019
On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent ResistanceAleksei A Stepanenko, Vladimir P Chekhonin
Virus Research|August 21, 2018
Tropism and transduction of oncolytic adenovirus 5 vectors in cancer therapy: Focus on fiber chimerism and mosaicism, hexon and pIXAleksei A Stepanenko, Vladimir P Chekhonin
Cancers|December 20, 2018
Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?Aleksei A Stepanenko, Vladimir P Chekhonin
Mutation Research. Reviews in Mutation Research|September 21, 2017
Transient and stable vector transfection: Pitfalls, off-target effects, artifactsAleksei A Stepanenko, Henry H Heng
Scientific Reports|August 10, 2021
A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugationAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Molecular Therapy Oncolytics|March 14, 2022
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?Victor A Naumenko, Aleksei A Stepanenko, Anastasiia V Lipatova, et al.
Frontiers in Immunology|February 23, 2024
The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapyAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Molecular Therapy. Oncology|February 20, 2026
Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/<i>SPAM1</i>-armed oncolytic adenovirus Ad5Δ24RGDAleksei A Stepanenko, Anastasiia O Sosnovtseva, Anastasiia A Vasiukova, et al.
Frontiers in Immunology|March 14, 2024
Systemic and local immunosuppression in glioblastoma and its prognostic significanceAleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, et al.
Pageof 2